The Effects of Medications on Myocardial Perfusion

Journal of the American College of Cardiology

Volumn 52, Issue 6, 2008, Pages 401-416

  Zoghbi, Gilbert J ^a   Dorfman, Todd A ^a   Iskandrian, Ami E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

beta blockers; calcium channel blockers; lipid lowering medications; myocardial perfusion imaging; SPECT

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DOBUTAMINE; FLUINDOSTATIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVINOLIN; NICORANDIL; NIFEDIPINE; NITRATE; PLACEBO; PRAVASTATIN; PROPRANOLOL; SIMVASTATIN;

ANGINA PECTORIS; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG MEGADOSE; EXPERIMENTAL STUDY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; LOW DRUG DOSE; MYOCARDIAL PERFUSION IMAGING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; POSITRON-EMISSION TOMOGRAPHY; STROKE VOLUME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 47849115887     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.04.035     Document Type: Review

References (118)

1. Iskandrian A., and Garcia E. Nuclear Cardiac Imaging: Principles and Applications. 4th edition (2008), Oxford University Press, England
2. Shaw L.J., Berman D.S., Maron D.J., et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 (2008) 1283-1291
3. Klocke F.J., Baird M.G., Lorell B.H., et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 42 (2003) 1318-1333
4. Henzlova M.J., Cerqueira M.D., Mahmarian J.J., and Yao S.S. Stress protocols and tracers. J Nucl Cardiol 13 (2006) e80-e90
5. Hansen C.L., Goldstein R.A., Akinboboye O.O., et al. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol 14 (2007) e39-e60
6. Iskandrian A.E., Garcia E.V., and Faber T. Analysis of serial images: a challenge and an opportunity. J Nucl Cardiol 15 (2008) 23-26
7. Golub R.J., Ahlberg A.W., McClellan J.R., et al. Interpretive reproducibility of stress Tc-99m sestamibi tomographic myocardial perfusion imaging. J Nucl Cardiol 6 (1999) 257-269
8. Zir L.M., Miller S.W., Dinsmore R.E., Gilbert J.P., and Harthorne J.W. Interobserver variability in coronary angiography. Circulation 53 (1976) 627-632
9. Harrison D.G., and Bates J.N. The nitrovasodilators. New ideas about old drugs. Circulation 87 (1993) 1461-1467
10. Katzung B., and Chatterjee K. Basic and Clinical Pharmacology. 7th edition (1998), Appleton and Lange, Stamford, CT
11. Sharir T., Rabinowitz B., Livschitz S., et al. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. J Am Coll Cardiol 31 (1998) 1540-1546
12. Sabharwal N.K., and Lahiri A. Antianginal medications and diagnostic accuracy of myocardial perfusion imaging. J Nucl Cardiol 10 (2003) 433-435
13. Habazettl H., Vollmar B., Christ M., Baier H., Conzen P.F., and Peter K. Heterogeneous microvascular coronary vasodilation by adenosine and nitroglycerin in dogs. J Appl Physiol 76 (1994) 1951-1960
14. Bottcher M., Madsen M.M., Randsbaek F., et al. Effect of oral nitroglycerin and cold stress on myocardial perfusion in areas subtended by stenosed and nonstenosed coronary arteries. Am J Cardiol 89 (2002) 1019-1024
15. Macho P., and Vatner S.F. Effects of nitroglycerin and nitroprusside on large and small coronary vessels in conscious dogs. Circulation 64 (1981) 1101-1107
16. Feldman R.L., Marx J.D., Pepine C.J., and Conti C.R. Analysis of coronary responses to various doses of intracoronary nitroglycerin. Circulation 66 (1982) 321-327
17. Kanatsuka H., Eastham C.L., Marcus M.L., and Lamping K.G. Effects of nitroglycerin on the coronary microcirculation in normal and ischemic myocardium. J Cardiovasc Pharmacol 19 (1992) 755-763
18. Cohen M.V., Downey J.M., Sonnenblick E.H., and Kirk E.S. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest 52 (1973) 2836-2847
19. Folts J.D., Stamler J., and Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 83 (1991) 2122-2127
20. Karlberg K.E., Torfgard K., Ahlner J., and Sylven C. Dose-dependent effect of intravenous nitroglycerin on platelet aggregation, and correlation with plasma glyceryl dinitrate concentration in healthy men. Am J Cardiol 69 (1992) 802-805
21. Salvemini D., Currie M.G., and Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest 97 (1996) 2562-2568
22. Lacoste L.L., Theroux P., Lidon R.M., Colucci R., and Lam J.Y. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol 73 (1994) 1058-1062
23. Chirkov Y.Y., Chirkova L.P., and Horowitz J.D. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol 80 (1997) 128-131
24. Aoki M., Sakai K., Koyanagi S., Takeshita A., and Nakamura M. Effect of nitroglycerin on coronary collateral function during exercise evaluated by quantitative analysis of thallium-201 single photon emission computed tomography. Am Heart J 121 (1991) 1361-1366
25. Goller V., Clausen M., Henze E., et al. Reduction of exercise-induced myocardial perfusion defects by isosorbide-5-nitrate: assessment using quantitative Tc-99m-MIBI-SPECT. Coron Artery Dis 6 (1995) 245-249
26. Lewin H.C., Hachamovitch R., Harris A.G., et al. Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi. J Nucl Cardiol 7 (2000) 342-353
27. Stegaru B., Loose R., Keller H., Buss J., and Wetzel E. Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 61 (1988) 74E-77E
28. Eldridge J.E., Burdick D.C., Jones R.H., and Hossack K.F. Comparison of nitroglycerin patches and nifedipine. J Cardiovasc Pharmacol 10 (1987) 315-319
29. Mahmarian J.J., Fenimore N.L., Marks G.F., et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 24 (1994) 25-32
30. Sciagra R. Nitrates and viability: a durable affair. J Nucl Med 44 (2003) 752-755
31. Tadamura E., Mamede M., Kubo S., et al. The effect of nitroglycerin on myocardial blood flow in various segments characterized by rest-redistribution thallium SPECT. J Nucl Med 44 (2003) 745-751
32. Slart R.H., Agool A., van Veldhuisen D.J., Dierckx R.A., and Bax J.J. Nitrate administration increases blood flow in dysfunctional but viable myocardium, leading to improved assessment of myocardial viability: a PET study. J Nucl Med 47 (2006) 1307-1311
33. Bisi G., Sciagra R., Santoro G.M., and Fazzini P.F. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 24 (1994) 1282-1289
34. Bisi G., Sciagra R., Santoro G.M., Rossi V., and Fazzini P.F. Technetium-99m-sestamibi imaging with nitrate infusion to detect viable hibernating myocardium and predict postrevascularization recovery. J Nucl Med 36 (1995) 1994-2000
35. Flotats A., Carrio I., Estorch M., et al. Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography. Eur J Nucl Med 24 (1997) 767-773
36. Bax J.J., Wijns W., Cornel J.H., Visser F.C., Boersma E., and Fioretti P.M. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 30 (1997) 1451-1460
37. He Z.X., Yang M.F., Liu X.J., et al. Association of myocardial viability on nitrate-augmented technetium-99m hexakis-2-methoxylisobutyl isonitrile myocardial tomography and intermediate-term outcome in patients with prior myocardial infarction and left ventricular dysfunction. Am J Cardiol 92 (2003) 696-699
38. Kula M., Tutus A., Unal S., Topsakal R., and Ergin A. Technetium-99m-tetrofosmin imaging with incremental nitroglycerin infusion to detect severely ischaemic but viable myocardium: a comparative study with thallium-201. Nucl Med Commun 24 (2003) 987-994
39. Djaballah W., Muller M.A., Angioi M., et al. Nitrate-enhanced gated SPECT in patients with primary angioplasty for acute myocardial infarction: evidence of a reversible and nitrate-sensitive impairment of myocardial perfusion. Eur J Nucl Med Mol Imaging 34 (2007) 1981-1990
40. Sorrentino A.R., Acampa W., Petretta M., Mainolfi C., Salvatore M., and Cuocolo A. Comparison of the prognostic value of SPECT after nitrate administration and metabolic imaging by PET in patients with ischaemic left ventricular dysfunction. Eur J Nucl Med Mol Imaging 34 (2007) 558-562
41. Guth B.D., Heusch G., Seitelberger R., and Ross Jr. J. Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 60 (1987) 738-746
42. Koepfli P., Wyss C.A., Namdar M., et al. Beta-adrenergic blockade and myocardial perfusion in coronary artery disease: differential effects in stenotic versus remote myocardial segments. J Nucl Med 45 (2004) 1626-1631
43. 2 supply and consumption. Eur J Pharmacol 142 (1987) 103-113
44. Matsuzaki M., Patritti J., Tajimi T., Miller M., Kemper W.S., and Ross Jr. J. Effects of beta-blockade on regional myocardial flow and function during exercise. Am J Physiol 247 (1984) H52-H60
45. Zmudka K., Dubiel J., Pieniazek P., et al. Influence of an early adrenergic blockade on thrombotic infarct size and myocardial metabolism. J Physiol Pharmacol 49 (1998) 333-352
46. Liu X.K., Engelman R.M., Agrawal H.R., and Das D.K. Preservation of membrane phospholipids by propranolol, pindolol, and metoprolol: a novel mechanism of action of beta-blockers. J Mol Cell Cardiol 23 (1991) 1091-1100
47. Monteiro P., Duarte A.I., Moreno A., Goncalves L.M., and Providencia L.A. Carvedilol improves energy production during acute global myocardial ischaemia. Eur J Pharmacol 482 (2003) 245-253
48. Schwarz E.R., Kersting P.H., Reffelmann T., et al. Cardioprotection by carvedilol: antiapoptosis is independent of beta-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther 8 (2003) 207-215
49. Feuerstein G.Z., Yue T.L., Cheng H.Y., and Ruffolo Jr. R.R. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 11 Suppl (1993) S41-S48
50. Hockings B., Saltissi S., Croft D.N., and Webb-Peploe M.M. Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging. Br Heart J 49 (1983) 83-89
51. Martin G.J., Henkin R.E., and Scanlon P.J. Beta blockers and the sensitivity of the thallium treadmill test. Chest 92 (1987) 486-487
52. Rainwater J., Steele P., Kirch D., LeFree M., Jensen D., and Vogel R. Effect of propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation 65 (1982) 77-81
53. Steele P., Sklar J., Kirch D., Vogel R., and Rhodes C.A. Thallium-201 myocardial imaging during maximal and submaximal exercise: comparison of submaximal exercise with propranolol. Am Heart J 106 (1983) 1353-1357
54. Narahara K.A., Thompson C.J., Hazen J.F., Brizendine M., and Mena I. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 117 (1989) 1030-1035
55. Shehata A.R., Gillam L.D., Mascitelli V.A., et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 80 (1997) 268-272
56. Bridges A.B., Kennedy N., McNeill G.P., Cook B., and Pringle T.H. The effect of atenolol on dipyridamole 201Tl myocardial perfusion tomography in patients with coronary artery disease. Nucl Med Commun 13 (1992) 41-46
57. Taillefer R., Ahlberg A.W., Masood Y., et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 42 (2003) 1475-1483
58. Bottcher M., Czernin J., Sun K., Phelps M.E., and Schelbert H.R. Effect of beta 1 adrenergic receptor blockade on myocardial blood flow and vasodilatory capacity. J Nucl Med 38 (1997) 442-446
59. Billinger M., Seiler C., Fleisch M., Eberli F.R., Meier B., and Hess O.M. Do beta-adrenergic blocking agents increase coronary flow reserve?. J Am Coll Cardiol 38 (2001) 1866-1871
60. Bottcher M., Refsgaard J., Madsen M.M., et al. Effect of antianginal medication on resting myocardial perfusion and pharmacologically induced hyperemia. J Nucl Cardiol 10 (2003) 345-352
61. Zervos G., Zusman R.M., Swindle L.A., Alpert N.M., Fischman A.J., and Gewirtz H. Effects of nifedipine on myocardial blood flow and systolic function in humans with ischemic heart disease. Coron Artery Dis 10 (1999) 185-194
62. Pepine C.J. The role of calcium antagonists in ischaemic heart disease. Eur Heart J 16 Suppl H (1995) 19-24
63. Tillmanns H., Neumann F.J., Parekh N., et al. Calcium antagonists and myocardial microperfusion. Drugs 42 Suppl 1 (1991) 1-6
64. Reimer K.A., and Jennings R.B. Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction. Am J Cardiol 55 (1985) 107B-115B
65. Sassen L.M., Bezstarosti K., Verdouw P.D., and Lamers J.M. Effects of nisoldipine on recovery of coronary blood flow, sarcoplasmic reticulum function and other biochemical parameters in post-ischaemic porcine myocardium. Biochem Pharmacol 41 (1991) 43-51
66. Park S.W., Tang X.L., Qiu Y., Sun J.Z., and Bolli R. Nisoldipine attenuates myocardial stunning induced by multiple coronary occlusions in conscious pigs and this effect is independent of changes in hemodynamics or coronary blood flow. J Mol Cell Cardiol 28 (1996) 655-666
67. Folts J.D. Inhibition of platelet activity in vivo by amlodipine alone and combined with aspirin. Int J Cardiol 62 Suppl 2 (1997) S111-S117
68. Ehring T., and Heusch G. Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion?. Cardiology 88 Suppl 1 (1997) 3-14 discussion 15-6
69. Yamazaki J., Ohsawa H., Uchi T., et al. Study of the efficacy of nicorandil in patients with ischaemic heart disease using Exercise-T1-201 myocardial tomography. Eur J Clin Pharmacol 44 (1993) 211-217
70. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
71. Boodhwani M., Nakai Y., Voisine P., et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 114 (2006) I402-I408
72. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., and Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
73. Ikeda Y., Young L.H., and Lefer A.M. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 41 (2003) 649-656
74. Cowled P.A., Khanna A., Laws P.E., Field J.B., Varelias A., and Fitridge R.A. Statins inhibit neutrophil infiltration in skeletal muscle reperfusion injury. J Surg Res 141 (2007) 267-276
75. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103 (2001) 993-999
76. Herman A.G., and Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 26 (2005) 1945-1955
77. Jones S.P., Gibson M.F., Rimmer III D.M., Gibson T.M., Sharp B.R., and Lefer D.J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
78. Calvert J.W., and Lefer D.J. Statin therapy and myocardial no-reflow. Br J Pharmacol 149 (2006) 229-231
79. Gueler F., Park J.K., Rong S., et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170 (2007) 1192-1199
80. Wilson S.H., Herrmann J., Lerman L.O., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 105 (2002) 415-418
81. Zhao J.L., Yang Y.J., Cui C.J., You S.J., and Gao R.L. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol 149 (2006) 243-249
82. Bonetti P.O., Wilson S.H., Rodriguez-Porcel M., Holmes Jr. D.R., Lerman L.O., and Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 40 (2002) 546-554
83. Gotto Jr. A.M. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 96 (2005) 34F-38F
84. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
85. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
86. de Lemos J.A., Blazing M.A., Wiviott S.D., et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
87. Pedersen T.R., Faergeman O., Kastelein J.J., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
88. Watts G.F., Lewis B., Brunt J.N., et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339 (1992) 563-569
89. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
90. Vita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81 (1990) 491-497
91. Schwartz R.G. Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy. J Nucl Cardiol 8 (2001) 528-532
92. Furchgott R.F. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 19 (1999) 235-251
93. Mostaza J.M., Gomez M.V., Gallardo F., et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 35 (2000) 76-82
94. Shaw L.J., and Berman D.S. Sequential single-photon emission computed tomography myocardial perfusion imaging. Am J Cardiol 96 (2005) 28J-39J
95. Leung W.H., Lau C.P., and Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 341 (1993) 1496-1500
96. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 (1994) 2519-2524
97. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
98. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., and Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 (1995) 488-493
99. Vita J.A., Yeung A.C., Winniford M., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102 (2000) 846-851
100. Eichstadt H.W., Eskotter H., Hoffman I., Amthauer H.W., and Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 76 (1995) 122A-125A
101. Eichstadt H.W., Abletshauser C.B., Stork T., and Weidinger G. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 35 (2000) 735-740
102. Hosokawa R., Nohara R., Linxue L., et al. Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Jpn Circ J 64 (2000) 177-182
103. Manfrini O., Pizzi C., Morgagni G., Fontana F., and Bugiardini R. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 93 (2004) 1391-1393
104. Schwartz R.G., Pearson T.A., Kalaria V.G., et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol 42 (2003) 600-610
105. Gould K.L., Martucci J.P., Goldberg D.I., et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 89 (1994) 1530-1538
106. Sdringola S., Nakagawa K., Nakagawa Y., et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol 41 (2003) 263-272
107. Dakik H.A., Kleiman N.S., Farmer J.A., et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation 98 (1998) 2017-2023
108. Mahmarian J.J., Dakik H.A., Filipchuk N.G., et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 48 (2006) 2458-2467
109. Gibbons R.J., Balady G.J., Beasley J.W., et al. ACC/AHA guidelines for exercise testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 30 (1997) 260-311
110. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 40 (2002) 1531-1540
111. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41 (2003) 159-168
112. Huggins G.S., Pasternak R.C., Alpert N.M., Fischman A.J., and Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98 (1998) 1291-1296
113. Baller D., Notohamiprodjo G., Gleichmann U., Holzinger J., Weise R., and Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
114. Guethlin M., Kasel A.M., Coppenrath K., Ziegler S., Delius W., and Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999) 475-481
115. Yokoyama I., Momomura S., Ohtake T., et al. Improvement of impaired myocardial vasodilatation due to diffuse coronary atherosclerosis in hypercholesterolemics after lipid-lowering therapy. Circulation 100 (1999) 117-122
116. Yokoyama I., Yonekura K., Inoue Y., Ohtomo K., and Nagai R. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol 8 (2001) 445-451
117. Ling M.C., Ruddy T.D., deKemp R.A., et al. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 149 (2005) 1137
118. Muller S., Konig I., Meyer W., and Kojda G. Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 44 (2004) 624-631